甲氨蝶呤联合短期超强效外用糖皮质激素对比单用长期超强效外用糖皮质激素治疗大疱性类天疱疮:多中心非劣效随机临床试验
这项多中心、随机、开放标签、非劣效试验纳入266例大疱性类天疱疮成人患者,比较短期超强效外用糖皮质激素联合低剂量甲氨蝶呤维持治疗与单用长期超强效外用糖皮质激素。主要终点9个月总生存率两组分别为86.5%和83.5%(p=0.498;HR 0.80,95%CI 0.40-1.50),达到非劣效;联合组9个月无复发生存率更高(68.4% vs 47.4%,p=0.042),但严重不良事件更频繁(每月每患者平均0.40 vs 0.19,p=0.005)。
要点
- 低剂量甲氨蝶呤维持治疗在9个月总生存率上非劣于长期超强效外用糖皮质激素。
- 联合治疗组9个月无复发生存率显著更高(68.4% vs 47.4%,p=0.042)。
- 联合治疗组严重不良事件更频繁,需权衡获益与毒性。
核心结论
- 低剂量甲氨蝶呤维持治疗在生存方面非劣于长期超强效外用糖皮质激素,且与降低复发风险相关,但以增加毒性为代价。
研究设计与样本
- 多中心、随机、开放标签、非劣效临床试验,纳入266例成人大疱性类天疱疮患者,平均年龄80.8岁。
主要发现
- 9个月总生存率:甲氨蝶呤联合短期超强效外用糖皮质激素组86.5%,单用长期超强效外用糖皮质激素组83.5%(p=0.498;HR 0.80,95%CI 0.40-1.50)。
- 生存率差异的90%置信区间下限为-4.6%,在预设非劣效界值15%之内,达到主要终点。
- 在28天内达到疾病控制的87.4%患者中,联合组复发31例,单用组52例;9个月无复发生存率分别为68.4%(95%CI 59.3-78.8)和47.4%(95%CI 37.7-59.5)(p=0.042)。
- 严重不良事件:联合组每月每患者平均0.40(95%CI 0.23-0.57),单用组0.19(95%CI 0.01-0.36)(p=0.005)。
关键数值与推荐
- 主要终点为非劣效设计,预设非劣效界值为15%。
- 联合组方案:超强效外用糖皮质激素(丙酸氯倍他索)使用1个月,联合低剂量甲氨蝶呤维持治疗;对照组为长期单用超强效外用糖皮质激素。
临床怎么用
- 对于大疱性类天疱疮成人患者,可考虑短期超强效外用糖皮质激素联合低剂量甲氨蝶呤维持治疗,以降低复发风险,但需密切监测严重不良事件。
局限性
- 研究为开放标签设计。
- 未纳入经验证的疾病活动度评分。
- 研究在临床试验条件下管理的高度选择的大疱性类天疱疮人群中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Superpotent topical corticosteroids (STS) are highly effective in bullous pemphigoid (BP), but prolonged use is associated with practical limitations and a risk of relapse. OBJECTIVE: To evaluate whether combining short-term STS with methotrexate (MTX) could maintain efficacy, reduce relapses, and preserve safety compared with prolonged STS alone. METHODS: In this multicentre, randomised, open-label, non-inferiority trial, adults with BP were assigned to receive either STS (clobetasol propionate) for one month plus low-dose MTX as maintenance (MTX + STS arm), or prolonged STS alone (STS arm). The primary endpoint was 9-month overall survival (OS), with a predefined non-inferiority margin of 15%. Secondary outcomes included relapse-free survival (RFS) and severe adverse events (SAE). RESULTS: Among 266 randomised patients (mean age 80.8 years), 9-month OS was 86.5% in the MTX + STS arm and 83.5% in the STS arm (p=0.498; hazard ratio [HR] 0.80, 95% CI 0.40-1.50). The lower limit of the 90% confidence interval for the difference in survival rates (-4.6%) remained within the predefined non-inferiority margin, meeting the primary endpoint. Among the 87.4% of patients who achieved disease control within 28 days, relapse occurred in 31 patients in the MTX + STS arm and 52 in the STS arm, corresponding to a 9-month RFS of 68.4% (95% CI 59.3-78.8) versus 47.4% (95% CI 37.7-59.5), respectively (p=0.042). SAE were more frequent in the MTX + STS arm than in the STS arm (mean number per patient per month 0.40 [95% CI 0.23-0.57] vs 0.19 [95% CI 0.01-0.36], p=0.005). LIMITATIONS: The study was open-label, did not include a validated disease activity score and was conducted in a selected BP population managed under clinical trial conditions. CONCLUSION: Maintenance therapy with low-dose MTX is non-inferior to prolonged STS in terms of survival and is associated with a reduced risk of relapse, at the cost of increased toxicity.
引用
- Dereure O, Bernard P, Chosidow O, et al. Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trial. Br J Dermatol. 2026. PMID: 41807108. doi:10.1093/bjd/ljag094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。